There has been little change in global TB incidence in the 21 century. Although case notification has increased, millions of people with TB each year remain unreached. Recently there has been increased recognition that many people with undiagnosed, potentially infectious TB do not experience or report TB symptoms. Symptom-agnostic screening (e.g. by chest X-ray) can effectively identify such forms of TB. While this activity is increasing globally and is beneficial to individuals screened, current levels fall far short of what is needed to impact transmission and population-level prevalence. Significant scale-up of symptom-agnostic screening across communities is required to improve treatment coverage and interrupt transmission. While there are major political, financial and health system challenges to undertaking such scale-up this is not without precedent. In the mid 20 century, in many countries which now experience a low TB burden, population level chest X-ray screening was successfully undertaken and contributed to the decline in TB. In this article we explore the challenges and opportunities that face countries wanting to scale-up symptom-agnostic screening and reflect on important lessons from the past.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijid.2025.107875 | DOI Listing |
Int J Infect Dis
March 2025
Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK.
There has been little change in global TB incidence in the 21 century. Although case notification has increased, millions of people with TB each year remain unreached. Recently there has been increased recognition that many people with undiagnosed, potentially infectious TB do not experience or report TB symptoms.
View Article and Find Full Text PDFFront Med (Lausanne)
October 2023
WHO Collaborating Centre for Tuberculosis and the Sydney Infectious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia.
In recognition of the high rates of undetected tuberculosis in the community, the World Health Organization (WHO) encourages targeted active case finding (ACF) among "high-risk" populations. While this strategy has led to increased case detection in these populations, the epidemic impact of these interventions has not been demonstrated. Historical data suggest that population-wide (untargeted) ACF can interrupt transmission in high-incidence settings, but implementation remains lacking, despite recent advances in screening tools.
View Article and Find Full Text PDFBackground: Amid all public health measures to contain COVID-19, the most challenging has been how to break the transmission chain. This has been even more challenging in low- and middle-income countries (LMICs). A public health emergency warrants a public health perspective, which comes down to prevention.
View Article and Find Full Text PDFCurr Neuropharmacol
February 2023
Sorbonne University, Alzheimer Precision Medicine (APM), AP-HP, Pitié-Salpêtrière Hospital, Boulevard de l'hôpital, Paris, France.
Nat Rev Neurol
September 2021
Neurology Business Group, Eisai Inc., Woodcliff Lake, NJ, USA.
Breakthroughs in the development of highly accurate fluid and neuroimaging biomarkers have catalysed the conceptual transformation of Alzheimer disease (AD) from the traditional clinical symptom-based definition to a clinical-biological construct along a temporal continuum. The AT(N) system is a symptom-agnostic classification scheme that categorizes individuals using biomarkers that chart core AD pathophysiological features, namely the amyloid-β (Aβ) pathway (A), tau-mediated pathophysiology (T) and neurodegeneration (N). This biomarker matrix is now expanding towards an ATX(N) system, where X represents novel candidate biomarkers for additional pathophysiological mechanisms such as neuroimmune dysregulation, synaptic dysfunction and blood-brain barrier alterations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!